CK-101

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CK-101 (RX-518) 是一种新型有效、突变选择性、不可逆、口服 EGFR 抑制剂，可克服 NSCLC 中 T790M 介导的耐药性。

CK-101 (RX-518) is a novel potent, mutant-selective, irreversible, orally available EGFR inhibitor, overcomes T790M-mediated resistance in NSCLC; specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward WT EGFR; selectively inhibits cell proliferation of cell lines expressing both the activating (HCC827, IC50 <15 nM) and resistance mutations (NCI-H1975, IC50 <5 nM); significantly inhibits tumor growth in EGFR-mutated NSCLC tumor xenograft models, with no activity in WT EGFR tumor xenograft model.Lung Cancer Phase 2 Clinical.

——

——

RX-518 | RX518 | CK101

Angiogenesis

EGFR

EGFR

Cancer

Lung Cancer

1660963-42-7

530.58

C29H28F2N6O2

>98% (HPLC)

DMSO : 125 mg/mL 235.60 mM; H2O : < 0.1 mg/mL

C=CC(NC1=CC=CC(C2=CC=CC3=CN=C(NC4=CC=C(N5CCN(CCO)CC5)C(F)=C4F)N=C23)=C1)=O

N-[3-[2-[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino]quinazolin-8-yl]phenyl]prop-2-enamide

(-20℃)

With Ice Pack

≥ 2 years